Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hyperfine, Inc. - Class A Common Stock
(NQ:
HYPR
)
1.020
+0.044 (+4.55%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Hyperfine, Inc. - Class A Common Stock
< Previous
1
2
3
Next >
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
Why VCI Global Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
January 12, 2024
Shares of VCI Global Limited (NASDAQ: VCIG) fell sharply in pre-market trading after the company announced pricing of $2.75 million public offering. VCI Global shares tumbled 29.5% to $1.10 in...
Via
Benzinga
Recap: Hyperfine Q3 Earnings
November 09, 2023
Via
Benzinga
Recap: Hyperfine Q1 Earnings
May 11, 2023
Via
Benzinga
Hyperfine's Earnings: A Preview
March 20, 2023
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
HYPR Stock Earnings: Hyperfine Meets EPS, Beats Revenue for Q2 2024
August 08, 2024
HYPR stock results show that Hyperfine met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
The Dollar Menu Portfolio: 7 Penny Stocks to Buy With Spare Change
May 24, 2024
These penny stocks under $1 have significant upside potential and relatively muted downside risk. Consider giving them a look!
Via
InvestorPlace
HYPR Stock Earnings: Hyperfine Beats EPS, Beats Revenue for Q1 2024
May 13, 2024
HYPR stock results show that Hyperfine beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
HYPR Stock Earnings: Hyperfine Beats EPS, Misses Revenue for Q4 2023
March 21, 2024
HYPR stock results show that Hyperfine beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
March 21, 2024
Via
Benzinga
Recap: Hyperfine Q4 Earnings
March 21, 2024
Via
Benzinga
Hyperfine Earnings Preview
March 20, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
January 12, 2024
We're starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
October 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 18, 2023
Via
Benzinga
Earnings Scheduled For August 14, 2023
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 18, 2023
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 18, 2023
Via
Benzinga
Earnings Scheduled For March 21, 2023
March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million.
Via
Benzinga
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 16, 2023
Via
Benzinga
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 14, 2023
Gainers Amesite Inc. (NASDAQ: AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 14, 2023
Via
Benzinga
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 31, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 31, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 20, 2022
Via
Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
December 13, 2022
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.